Table 1.
Minimum inhibitory concentration (MIC) values (μg mL-1) of platensimycin and analogs against methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus faecium (VREF), and E. coli.
| Entry | Compound | MRSA | VREF | E. coli |
|---|---|---|---|---|
| 1a |  |
0.2–0.4 | 0.4–0.8 | >88 |
| 2a |  |
1.1–2.2 | 1.1–2.2 | >88 |
| 3b |  |
1.3–1.8 | 1.3–1.8 | >88 |
| 4b |  |
3.5–4.3 | 6.5–8.6 | >86 |
| 5b |  |
8.0–10 | >80 | >80 |
| 6 b |  |
17–20 | >83 | >83 |
| 7c |  |
>88 | >88 | >88 |
| 8 |  |
>86 | >86 | >86 |
| 9b |  |
>69 | >69 | >69 |
| 10a |  |
>85 | >85 | >85 |
| 11a |  |
>85 | >85 | >85 |
| 12 a |  |
>82 | >82 | >82 |
| 13 a |  |
>73 | >73 | >73 |
| 14 a |  |
37–58 | >58 | >58 |
a
Only the isomer shown was tested in the antibacterial assay.
b
Both the isomer shown and its enantiomer were tested separately in the antibacterial assay. The latter isomer was found to be inactive in the investigated range.
c
The compound was tested as a racemic mixture in the antibacterial assay.